Search

Your search keyword '"Foroozesh, Maryam"' showing total 202 results
Start Over Author "Foroozesh, Maryam"
202 results on '"Foroozesh, Maryam"'

1. Student Grade Evaluation, Survey Feedback, and Lessons Learned during the COVID-19 Pandemic: A Comparative Study of Virtual vs. In-Person Offering of a Freshman-Level General Chemistry II Course in Summer at Xavier University of Louisiana

Author

Goyal, Navneet, Abdulahad, Asem I., Privett, Janet A., Verma, Abha, Foroozesh, Maryam, and Coston, Tiera S.

Abstract

A primary motivation for this study was to compare student perceptions and performance within a virtual learning environment to the traditional in-person learning experience for the General Chemistry II course taught during a 5-week summer session at Xavier University of Louisiana, a minority serving institution. The authors present quantitative and qualitative analyses including the comparison of student performance on exams during the COVID-19 remote learning experience with exam performance over a 3-year period of conventional in-person instruction. In this article, student grades, survey feedback, and learning outcomes are outlined. This study was performed to assist the faculty in improving and enriching the course content and its delivery, as they coped with the transition to a virtual learning environment imposed by the COVID-19 pandemic.

Published
2022

3. Baseline Characteristics of the 2015-2019 First Year Student Cohorts of the NIH Building Infrastructure Leading to Diversity (BUILD) Program.

Author

Norris, Keith C, McCreath, Heather E, Hueffer, Karsten, Aley, Stephen B, Chavira, Gabriela, Christie, Christina A, Crespi, Catherine M, Crespo, Carlos, D'Amour, Gene, Eagan, Kevin, Echegoyen, Lourdes E, Feig, Andrew, Foroozesh, Maryam, Guerrero, Lourdes R, Johanson, Kelly, Kamangar, Farin, Kingsford, Laura, LaCourse, William, Maccalla, Nicole Marie-Gerardi, Márquez-Magaña, Leticia, Mathur, Ambika, Maton, Kenneth, Mehravaran, Shiva, Morales, Danielle X, Nakazono, Terry, Ofili, Elizabeth, Okuyemi, Kolawole, Ott, Laura, Parangan-Smith, Audrey, Pfund, Christine, Purnell, Dawn, Reynolds, Arleigh, Rous, Phillip J, Saetermoe, Carrie, Snyder, Katherine, Vishwanatha, Jamboor K, Wagler, Amy, Wallace, Steven P, and Seeman, Teresa

Subjects
Epidemiology, Public Health, Health Sciences, Clinical Research, American Indian or Alaska Native, Quality Education, Adolescent, Adult, Black or African American, Asian, Biomedical Research, Cultural Diversity, Educational Status, Female, Government Programs, Hispanic or Latino, Humans, Income, Male, Middle Aged, National Institutes of Health (U.S.), Native Hawaiian or Other Pacific Islander, Prospective Studies, Students, Surveys and Questionnaires, United States, Universities, White People, Workforce, Young Adult, Diversity, Workforce Training, Underrepresented Students, Public Health and Health Services, Public health
Abstract

ObjectiveThe biomedical/behavioral sciences lag in the recruitment and advancement of students from historically underrepresented backgrounds. In 2014 the NIH created the Diversity Program Consortium (DPC), a prospective, multi-site study comprising 10 Building Infrastructure Leading to Diversity (BUILD) institutional grantees, the National Research Mentoring Network (NRMN) and a Coordination and Evaluation Center (CEC). This article describes baseline characteristics of four incoming, first-year student cohorts at the primary BUILD institutions who completed the Higher Education Research Institute, The Freshmen Survey between 2015-2019. These freshmen are the primary student cohorts for longitudinal analyses comparing outcomes of BUILD program participants and non-participants.DesignBaseline description of first-year students entering college at BUILD institutions during 2015-2019.SettingTen colleges/universities that each received

Published
2020

6. Ethyl 2-[(2-oxo-2H-chromen-6-yl)oxy]acetate.

Author

Goyal, Navneet, Donahue, James P., Thompson, Anthony, Xiaodong Zhang, Mague, Joel T., and Foroozesh, Maryam

Subjects
ACETATES, ETHYL group, SPACE groups, HYDROGEN bonding, ATOMS, CRYSTAL structure
Abstract

Ethyl 2-[(2-oxo-2H-chromen-6-yl)­oxy]acetate, C13H12O5, a member of the pharmacologically important class of coumarins, crystallizes in the monoclinic C2/c space group in the form of sheets, within which mol­ecules are related by inversion centers and 21 axes. Multiple C—H⋯O weak hydrogen-bonding inter­actions reinforce this pattern. The planes of these sheets are oriented in the approximate direction of the ac face diagonal. Inter­sheet inter­actions are a combination of coumarin system π–π stacking and additional C—H⋯O weak hydrogen bonds between ethyl acet­oxy groups. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. TEACHING AND LEARNING CENTERS: A STEM PERSPECTIVE ON THE IMPACT FOR AN INSTITUTION OF HIGHER EDUCATION

Author

Foroozesh, Maryam

Subjects
Article
Abstract

"The true pillar of quality higher education is well-trained, effective, and knowledgeable faculty who are invested in the success of their students. The discipline-specific knowledge required for entering an academic career as a STEM faculty member is mostly gained through academic graduate and post-doctoral training. However, formal preparation in the areas of teaching and mentoring are often lacking, and typically occur through observation of more senior colleagues. In reality, when it comes to teaching and mentoring, many STEM faculty members “build the plane while flying it,” and mainly learn by trial and error. As all interactions between faculty and students can seriously impact student retention and success, there is a great need for faculty development opportunities in these areas. The focus of this communication is on the impact of mentor and pedagogical training at Xavier University of Louisiana from the STEM faculty perspective."

Published
2022

37. Structure–Function Studies of Naphthalene, Phenanthrene, Biphenyl, and Their Derivatives in Interaction with and Oxidation by Cytochromes P450 2A13 and 2A6

Author

Shimada, Tsutomu, primary, Takenaka, Shigeo, additional, Kakimoto, Kensaku, additional, Murayama, Norie, additional, Lim, Young-Ran, additional, Kim, Donghak, additional, Foroozesh, Maryam K., additional, Yamazaki, Hiroshi, additional, Guengerich, F. Peter, additional, and Komori, Masayuki, additional

Published
2016
Full Text
View/download PDF

38. DESIGN, SYNTHESIS, AND EVALUATION OF CARBAZOLE ANALOGS AS POTENTIAL CYTOCHROME P450 INHIBITORS

Author

Foroozesh, Maryam, Jiang, Quan, Sridhar, Jayalakshmi, Liu, Jiawang, Dotson, Brandan, and McClain, Erika

Subjects
Article
Abstract

Carbazoles are a class of nitrogen-containing aromatic heterocyclic compounds. They not only have various biological activities (e.g. antibacterial, anti-inflammatory, antitumor), but also exhibit useful properties as organic materials due to their special structures. Cytochrome P450 enzymes are a superfamily of hemoproteins involved in the metabolism of endogenous and exogenous compounds including many drugs and environmental chemicals. Some aryl and arylalkyl acetylenes, and propargyl ethers have been shown to act as inhibitors of certain P450s. In an attempt to improve the potency and selectivity of inhibition, we have focused our attention on the design and synthesis of a new series of carbazole analogs, a few of which contain a propargyl ether functional group. For this project, eight carbazole analogs have been synthesized and characterized.

Published
2013

39. Potent Mechanism-Based Inactivation Of Cytochrome P450 2B4 By 9-Ethynylphenanthrene: Implications For Allosteric Modulation Of Cytochrome P450 Catalysis1

Author

Zhang, Haoming, Gay, Sean C., Shah, Manish, Foroozesh, Maryam, Liu, Jiawang, Osawa, Yoichi, Zhang, Qinghai, Stout, C. David, Halpert, James R., and Hollenberg, Paul F.

Subjects
Molecular Docking Simulation, Kinetics, Allosteric Regulation, Protein Conformation, Catalytic Domain, Animals, Aryl Hydrocarbon Hydroxylases, Rabbits, Phenanthrenes, Crystallography, X-Ray, Cytochrome P450 Family 2, Article, Protein Binding
Abstract

The mechanism-based inactivation of cytochrome P450 2B4 (CYP2B4) by 9-ethynylphenanthrene (9EP) has been investigated. The partition ratio and k(inact) are 0.2 and 0.25 min(-1), respectively. Intriguingly, the inactivation exhibits sigmoidal kinetics with a Hill coefficient of 2.5 and an S(50) of 4.5 μM indicative of homotropic cooperativity. Enzyme inactivation led to an increase in mass of the apo-CYP2B4 by 218 Da as determined by electrospray ionization liquid chromatography and mass spectrometry, consistent with covalent protein modification. The modified CYP2B4 was purified to homogeneity and its structure determined by X-ray crystallography. The structure showed that 9EP is covalently attached to Oγ of Thr 302 via an ester bond, which is consistent with the increased mass of the protein. The presence of the bulky phenanthrenyl ring resulted in inward rotations of Phe 297 and Phe 206, leading to a compact active site. Thus, binding of another molecule of 9EP in the active site is prohibited. However, results from the quenching of 9EP fluorescence by unmodified or 9EP-modified CYP2B4 revealed at least two binding sites with distinct affinities, with the low-affinity site being the catalytic site and the high-affinity site on the protein periphery. Computer-aided docking and molecular dynamics simulations with one or two ligands bound revealed that the high-affinity site is situated at the entrance of a substrate access channel surrounded by the F' helix, β1-β2 loop, and β4 loop and functions as an allosteric site to enhance the efficiency of activation of the acetylenic group of 9EP and subsequent covalent modification of Thr 302.

Published
2013

40. The sphingosine kinase 2 inhibitor ABC294640 displays anti‐non‐small cell lung cancer activities <italic>in vitro</italic> and <italic>in vivo</italic>.

Author

Dai, Lu, Smith, Charles D., Foroozesh, Maryam, Miele, Lucio, and Qin, Zhiqiang

Abstract

Non‐small cell lung cancer (NSCLC) accounts for about 85‐90% of lung cancer cases, and is the number one killer among cancers in the United States. The majorities of lung cancer patients do not respond well to conventional chemo‐ and/or radio‐therapeutic regimens, and have a dismal 5‐year survival rate of ∼15%. The recent introduction of targeted therapy and immunotherapy gives new hopes to NSCLC patients, but even with these agents, not all patients respond, and responses are rarely complete. Thus, there is still an urgent need to identify new therapeutic targets in NSCLC and develop novel anti‐cancer agents. Sphingosine kinase 2 (SphK2) is one of the key enzymes in sphingolipid metabolism. SphK2 expression predicts poor survival in NSCLC patients, and is associated with Gefitinib‐resistance. In this study, the anti‐NSCLC activities of ABC294640, the only first‐in‐class orally available inhibitor of SphK2, were explored. The results obtained indicate that ABC294640 treatment causes significant NSCLC cell apoptosis, cell cycle arrest and suppression of tumor growth in vitro and in vivo. Moreover, lipidomics analyses revealed the complete signature of ceramide and dihydro(dh)‐ceramide species in the NSCLC cell‐lines with or without ABC294640 treatment. These findings indicate that sphingolipid metabolism targeted therapy may be developed as a promising strategy against NSCLC. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

42. A Ligand-Based Drug Design. Discovery of 4-Trifluoromethyl-7,8-pyranocoumarin as a Selective Inhibitor of Human Cytochrome P450 1A2

Author

Liu, Jiawang, primary, Pham, Peter T., additional, Skripnikova, Elena V., additional, Zheng, Shilong, additional, Lovings, La’nese J., additional, Wang, Yuji, additional, Goyal, Navneet, additional, Bellow, Sydni M., additional, Mensah, Lydia M., additional, Chatters, Amari J., additional, Bratton, Melyssa R., additional, Wiese, Thomas E., additional, Zhao, Ming, additional, Wang, Guangdi, additional, and Foroozesh, Maryam, additional

Published
2015
Full Text
View/download PDF

44. A Drug Discovery Partnership for Personalized Breast Cancer Therapy

Author

XAVIER UNIV OF LOUISIANA NEW ORLEANS, Foroozesh, Maryam, Weise, Thomas, Sridhar, Jayalakshmi, Beckman, Barbara, Burow, Matthew, Jones, Frank, Stevens, Cheryl, XAVIER UNIV OF LOUISIANA NEW ORLEANS, Foroozesh, Maryam, Weise, Thomas, Sridhar, Jayalakshmi, Beckman, Barbara, Burow, Matthew, Jones, Frank, and Stevens, Cheryl

Abstract

Xavier University of Louisiana is in the unique position of developing capability in drug discovery especially in the areas of cancer and health disparities. A significant proportion of the funded research on Xavier s campus including collaborative projects involving Tulane University are related to cancer, drug design, synthesis, and drug delivery. This project expands the partnership between Xavier University and Tulane Cancer Center to develop and validate drugs for breast cancer therapy. The Drug Design Team at Xavier consists of experts in computer-aided drug design methods and synthesis and has formed a productive partnership with the Cancer Drug Validation Team at the Tulane Cancer Center. This inter-university collaboration involves training Xavier researchers, including undergraduate students, to carryout the experiments necessary to determine if new compounds would be suitable as new drugs to treat breast cancer. Three separate studies are ongoing as subprojects: (1) Design and synthesis of novel ceramide analogs that potentially reverse chemotherapy drug resistance, (2) Design and synthesis of small molecule inhibitors of HER2 tyrosine kinase to suppress tumorigenesis, and (3) Identification of compounds with the potential for estrogen receptor activity., The original document contains color images.

Published
2014

45. Ethynylflavones, Highly Potent, and Selective Inhibitors of Cytochrome P450 1A1

Author

Goyal, Navneet, primary, Liu, Jiawang, additional, Lovings, La’Nese, additional, Dupart, Patrick, additional, Taylor, Shannon, additional, Bellow, Sydni, additional, Mensah, Lydia, additional, McClain, Erika, additional, Dotson, Brandan, additional, Sridhar, Jayalakshmi, additional, Zhang, Xiaoyi, additional, Zhao, Ming, additional, and Foroozesh, Maryam, additional

Published
2014
Full Text
View/download PDF

46. A Drug Discovery Partnership for Personalized Breast Cancer Therapy

Author

XAVIER UNIV OF LOUISIANA NEW ORLEANS, Foroozesh, Maryam, Weise, Thomas, Sridhar, Jayalakshmi, Beckman, Barbara, Burow, Matthew, Jones, Frank, Stevens, Cheryl, XAVIER UNIV OF LOUISIANA NEW ORLEANS, Foroozesh, Maryam, Weise, Thomas, Sridhar, Jayalakshmi, Beckman, Barbara, Burow, Matthew, Jones, Frank, and Stevens, Cheryl

Abstract

Xavier University of Louisiana is in the unique position of developing capability in drug discovery especially in the areas of cancer and health disparities. A significant proportion of the funded research on Xavier s campus including collaborative projects involving Tulane University are related to cancer, drug design, synthesis, and drug delivery. This project expands the partnership between Xavier University and Tulane Cancer Center to develop and validate drugs for breast cancer therapy. The Drug Design Team at Xavier consists of experts in computer-aided drug design methods and synthesis and has formed a productive partnership with the Cancer Drug Validation Team at the Tulane Cancer Center. This inter-university collaboration involves training Xavier researchers, including undergraduate students, to carryout the experiments necessary to determine if new compounds would be suitable as new drugs to treat breast cancer. Three separate studies are ongoing as subprojects: (1) Design and synthesis of novel ceramide analogs that potentially reverse chemotherapy drug resistance, (2) Design and synthesis of small molecule inhibitors of HER2 tyrosine kinase to suppress tumorigenesis, and (3) Identification of compounds with the potential for estrogen receptor activity., The original document contains color images.

Published
2013

48. A Drug Discovery Partnership for Personalized Breast Cancer Therapy

Author

XAVIER UNIV OF LOUISIANA NEW ORLEANS, Foroozesh, Maryam, XAVIER UNIV OF LOUISIANA NEW ORLEANS, and Foroozesh, Maryam

Abstract

Xavier University of Louisiana is in the unique position of developing capability in drug discovery especially in the areas of cancer and health disparities. A significant proportion of the funded research on Xavier s campus including collaborative projects involving Tulane University are related to cancer, drug design, synthesis, and drug delivery. This project expands the partnership between Xavier University and Tulane Cancer Center to develop and validate drugs for breast cancer therapy. The Drug Design Team at Xavier consists of experts in computer aided drug design methods and synthesis and has formed a productive partnership with the Cancer Drug Validation Team at the Tulane Cancer Center. This inter-university collaboration involves training Xavier researchers, including undergraduate students, to carryout the experiments necessary to determine if new compounds would be suitable as new drugs to treat breast cancer. Three separate studies are ongoing as subprojects: (1) Design and synthesis of novel ceramide analogs that potentially reverse chemotherapy drug resistance, (2) Design and synthesis of small molecule inhibitors of HER2 tyrosine kinase to suppress tumorigenesis, and (3) Identification of compounds with the potential for estrogen receptor activity., The original document contains color images.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results